30+ Popular Targets in Drug Discovery and Design: A Comprehensive Guide

30+ Popular Targets in Drug Discovery and Design: A Comprehensive Guide

This guide explores over 30 popular targets for drug discovery and design, providing valuable insights for researchers and industry professionals.

Top Drug Targets Ranked by Popularity

Here's a list of popular targets, ranked by their current prominence in drug development:

1. CD47: A cell surface protein overexpressed in various cancers, inhibiting phagocytosis by macrophages.2. PD-1/PD-L1: Immune checkpoint proteins that regulate T cell activation, often exploited by tumors to evade immune responses.3. HER2: A receptor tyrosine kinase overexpressed in certain cancers, promoting cell growth and proliferation.4. EGFR: A receptor tyrosine kinase involved in cell growth and survival, often mutated or overexpressed in cancers.5. BCR-ABL: A fusion oncogene driving chronic myeloid leukemia (CML).6. ALK: A receptor tyrosine kinase involved in cell signaling, frequently altered in various cancers.7. BRAF: A serine/threonine kinase, frequently mutated in melanoma and other cancers.8. KRAS: A GTPase protein, frequently mutated in various cancers, driving uncontrolled cell growth.9. PI3K: A lipid kinase involved in cell growth, proliferation, and survival, frequently dysregulated in cancer.10. JAK2: A tyrosine kinase involved in cytokine signaling, implicated in myeloproliferative neoplasms.11. BTK: A tyrosine kinase crucial for B cell development, targeted in B cell malignancies.12. PARP: Enzymes involved in DNA repair, exploited in cancer therapy by inducing synthetic lethality.13. VEGF: A signaling protein promoting angiogenesis, often targeted in cancer to inhibit blood vessel formation.14. TNF-alpha: A pro-inflammatory cytokine involved in various inflammatory diseases, including rheumatoid arthritis.15. IL-6: A pro-inflammatory cytokine implicated in various inflammatory and autoimmune diseases.16. IL-17: A pro-inflammatory cytokine involved in autoimmune diseases like psoriasis. 17. IL-23: A pro-inflammatory cytokine implicated in inflammatory bowel disease and psoriasis.18. CD20: A cell surface receptor expressed on B cells, targeted in B cell malignancies and autoimmune diseases.19. CD38: A cell surface receptor expressed on immune cells, targeted in multiple myeloma.20. CDK4/6: Cyclin-dependent kinases involved in cell cycle regulation, targeted in cancer to inhibit cell proliferation.21. FLT3: A receptor tyrosine kinase, frequently mutated in acute myeloid leukemia (AML).22. IDH1: An enzyme involved in cellular metabolism, mutated in various cancers.23. IDH2: An enzyme involved in cellular metabolism, mutated in various cancers.24. P53: A tumor suppressor protein, frequently mutated in cancer.25. HSP90: A chaperone protein, involved in protein folding and stability, exploited in cancer therapy.26. HDAC: Enzymes that regulate gene expression, targeted in cancer and other diseases.27. mTOR: A serine/threonine kinase regulating cell growth and metabolism, targeted in cancer and other diseases.28. TGF-beta: A cytokine with diverse roles in cell growth, differentiation, and immunity, implicated in fibrosis and cancer.29. GPCR (G-protein coupled receptors): A large family of cell surface receptors, involved in diverse physiological processes, making them attractive drug targets.30. SGLT2: A sodium-glucose cotransporter involved in glucose reabsorption in the kidneys, targeted for type 2 diabetes.31. PPAR-gamma: A nuclear receptor involved in lipid metabolism and glucose homeostasis, targeted for type 2 diabetes.

Companies at the Forefront of Drug Development

Many pharmaceutical and biotechnology companies are actively researching and developing drugs targeting these proteins. Below are examples of companies working on each target:

• CD47: Trillium Therapeutics, Forty Seven Inc.* PD-1/PD-L1: Merck, Bristol-Myers Squibb, Roche, AstraZeneca* HER2: Genentech, Pfizer, Novartis* EGFR: Roche, AstraZeneca, Pfizer* BCR-ABL: Novartis, Bristol-Myers Squibb* ALK: Pfizer, Novartis* BRAF: Novartis, Pfizer* KRAS: Amgen, Mirati Therapeutics* PI3K: Gilead Sciences, Novartis* JAK2: Incyte Corporation, Gilead Sciences* BTK: AbbVie, Pharmacyclics* PARP: AstraZeneca, GlaxoSmithKline* VEGF: Roche, Regeneron Pharmaceuticals* TNF-alpha: AbbVie, Johnson & Johnson* IL-6: Roche, Regeneron Pharmaceuticals* IL-17: Eli Lilly, Novartis* IL-23: Janssen Biotech, AbbVie* CD20: Roche, Biogen* CD38: Bristol-Myers Squibb, GlaxoSmithKline* CDK4/6: Pfizer, Novartis* FLT3: Astellas Pharma, Daiichi Sankyo* IDH1: Agios Pharmaceuticals* IDH2: Agios Pharmaceuticals* P53: AstraZeneca, Pfizer* HSP90: Novartis, Synta Pharmaceuticals* HDAC: Celgene, Novartis* mTOR: Pfizer, Novartis* TGF-beta: Roche, Eli Lilly* GPCR: Novartis, Pfizer* SGLT2: AstraZeneca, Johnson & Johnson* PPAR-gamma: Takeda Pharmaceuticals, Novo Nordisk

Note: This list is not exhaustive. Many other companies are involved in drug discovery research targeting these and other promising candidates.

This guide provides a valuable starting point for understanding popular targets in drug discovery. Remember to consult scientific literature and industry resources for the most up-to-date information.